HUE030788T2 - Orális dózisforma, amely likarbazepin acetátot tartalmaz - Google Patents
Orális dózisforma, amely likarbazepin acetátot tartalmaz Download PDFInfo
- Publication number
- HUE030788T2 HUE030788T2 HUE08842368A HUE08842368A HUE030788T2 HU E030788 T2 HUE030788 T2 HU E030788T2 HU E08842368 A HUE08842368 A HU E08842368A HU E08842368 A HUE08842368 A HU E08842368A HU E030788 T2 HUE030788 T2 HU E030788T2
- Authority
- HU
- Hungary
- Prior art keywords
- binder
- disintegrant
- composition
- pharmaceutical composition
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1 Gyógyászati keszumèny, amely eszükatbszépsn aeetáíot (esltearbazepine acétate) tartalmaz Kombinációban egy kötőanyaggal (binder) és egy szétesés! elősegítő szerrel (óisímegrent), éttel az esziikarbazepin acélát Ms szétesést elősegít szer sgy része öíyan szemcsékben (gránátom) van seien, -amely nedves grppiáissssi mn eiésztlteí és a szétesést elősegítő szer maradék része szemcsén ikívp (emragranuiar), és ahol a késziteÍényolysrrtlftegatsöföséggé! piík dériSty) bír, amely jegaíéöb 0,3 géni, %, At 1. igénypont szerinti gyógyászati készítmény aim! s: készítmény legalább Ö$ gépi tertegatebriiseggel bin 3. ht 1> vagy % Ipénypbntszénntí gyógyászati készítmény amely tartalmaz továbbá szemcsén kívüli síkosíióarspgoi (lubúcaní). A. Az 14, Igénypontok bármelyike szerinti gyógyászati készítmény, ahol a szétesést éioségitó szer kroszkarmeilóz (croscarrneliose) nátrium, §. Az 14. igénypontok lármetyiké Ädttellfi: Ä * kötőanyag pövtpn (vegyis ροΙίνίηΙίρΜΡοη),
8, Gyógyászati kompozíció, amely az 1-8. igénypontok bármelyike szerinti készítményből van gyártva.
7, M Igénypont szerinti gyógyászati: kompozíció, aboi a kompozíció tabletta, és iöitősölya (apparent density) a 0,5 pmí és 1,5 géni közötti tartományban van. 8 A! igénypert Szerinti gyógyászati kompozíció, and a kompozíció összíömege 0,5 tömeg - 70: tömeg % szétesést elösegító szeri tartalmaz.
9. A Sigénypont szennii gyógyászati kompezys, alte! s kompózíslö őssziömege 0,§ terriég % -· ?δ tömeg 1 kötöanyagöttartairnaz. 1ö, A β, igénypont szedni gyógyászáti kömpöziöiö, aboi à kompozíció ossztőmégé ö,í tömeg % -10 tömeg % sikositösnyagot tartalmaz.
11. Aikslmrizása egy, az 1-5 igénypontok bármelyike szerinti gyógyászati készítménynek gyógyászati kompozíció klaiakítására.
12, All tginypont szerinti dkalmazés, abdl a gyógyiszaö KsrnpózidótstMte vagy kapszula; 18, gprás gyógyászati készítmény és kívánt esetben orális dözisterma elkiszitesÄ ameiy terma Üfel«: klianyagot és szétesést elősegítő szert; az. eljárás a következő lépéseket taitaimazza: - Osszekevegük az esztikarbazepin aceíátet aki&myag teljés mennyiségének egy : részévét és a szétesést éiségite anyag egy részével; - szolgáltatunk egy szemcsésíto folyadékot (granulation iiguíd); - feioislpk vagy óiszporgátjuk a kötőanyag teljes mennyiségének maradék bányádét a szenteséstíé folyadékban; • granuláljak: a keveréket a keverési lépésből, alkalmazva azt a szemesésitö folyadékot, amely a feloldási vagy diszponálás; lépést#; kefeikszeit, hogy így alakítsunk ki szemcsékéi; - érintkezésbe hoæatk a ezerappra? a szétesést elősegítő SZer maradék részévéi; hogy olyan készítményt alakítsunk ki, amelynek téríogatsörűsége legalább 0;3 g/mi; és - kívánt esetoen kialakítunk egy oráiis dőzlsformaí. 14. A13. igénypont azébnf après, ahol az eazlikarbazepinaeetàt 2D-M$meg % ÂanyagéSszfnegfiyiséggsi van őss$É$$ii, 15 A13. igénypont szenntí epréé, ohoí:38-?ö:lömeg % szétesést elősegítő anyag öSszméíaiyiség vanléíen a szeftíösékOén. 13 A13-15. Igénypontok bármelyike szennü eljárás, ahol a szemcsése folyadék víz. etanoi, vagy ezek keveréke. 17. A. 13-16. igénypentök:|ÉP®iyike azeÉ5i e|éráÁ;akei az eljárás tartalmazza továbbá a szemcsék szárításának lépését. 18. A13-17. igénypontok bármelyike azerlnl epras, alpi a késgitmény prills é^f^iâÂ'lSâkitéô. 18. A18, igénypont szerinti eljárás, shoi az orális dézísforma össztomege 0,5-70 tömeg % szétesést elősegítő szert tartalmaz. 20, A18, Igénypont szerinti eljárás, shoi az orális dézlsforma összlőrnega 0,5-70 tömeg % kötőanyagot tartalmaz. 21, A18. Igénypont: szanol eljárás, shot az orális 8öÉsio?mo éssztémege 0,1 -10 tömeg % sikpsítószert taf talmaz, 22, A 13-21. igényponick: bármelyike: szénát sprás,: abpkaz orális dézisiorma tabletta, is a formázási lépés magában téglái összenyomást (compressionj. 23, A22;:|éíiyppni szennii eljárás, iappsmohdonsily; rendelkezik. 24, A13-21, IgénypntQklarmeiyiké szenrtt! épás. áhoi az orális dizisfonna kapszéia-szöfe ferma. és a fermázási lépés magéban foglalja egy kapszula: megtöltéséi.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98279007P | 2007-10-26 | 2007-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE030788T2 true HUE030788T2 (hu) | 2017-06-28 |
Family
ID=40254311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE08842368A HUE030788T2 (hu) | 2007-10-26 | 2008-10-24 | Orális dózisforma, amely likarbazepin acetátot tartalmaz |
Country Status (24)
Country | Link |
---|---|
US (5) | US8372431B2 (hu) |
EP (2) | EP3202392B1 (hu) |
JP (4) | JP2011500797A (hu) |
KR (3) | KR20170004034A (hu) |
CN (1) | CN101848698A (hu) |
AR (1) | AR069031A1 (hu) |
AU (1) | AU2008317584B2 (hu) |
BR (1) | BRPI0818680B1 (hu) |
CA (1) | CA2703313C (hu) |
CY (1) | CY1118350T1 (hu) |
DK (1) | DK2214636T3 (hu) |
ES (2) | ES2898202T3 (hu) |
HR (1) | HRP20161329T1 (hu) |
HU (1) | HUE030788T2 (hu) |
IL (1) | IL205160A0 (hu) |
LT (1) | LT2214636T (hu) |
MX (1) | MX2010004323A (hu) |
PL (1) | PL2214636T3 (hu) |
PT (2) | PT3202392T (hu) |
RS (1) | RS55376B1 (hu) |
RU (1) | RU2546521C2 (hu) |
SI (1) | SI2214636T1 (hu) |
UA (1) | UA110012C2 (hu) |
WO (1) | WO2009054743A1 (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
MX2012000892A (es) | 2009-07-21 | 2012-06-01 | Keryx Biopharmaceuticals Inc | Formas de dosificacion de citrato ferrico. |
RU2012106827A (ru) | 2009-07-27 | 2013-09-10 | БИАЛ-ПОРТЕЛА энд КА., С.А. | Применение производных 5н-дибенз/в, f/азепин-5-карбоксамида для лечения фибромиалгии |
CA2777937C (en) | 2009-10-26 | 2017-08-29 | Merck Sharp & Dohme Corp. | Solid pharmaceutical compositions containing an integrase inhibitor |
US20120121703A1 (en) * | 2010-07-20 | 2012-05-17 | Japan Tobacco Inc. | Tablet containing ferric citrate |
TR201008460A1 (tr) * | 2010-10-15 | 2012-05-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Eslikarbazepinin saşe formülasyonları. |
UA115420C2 (uk) | 2010-12-31 | 2017-11-10 | Біал-Портела Енд Ка., С.А. | Тверда фармацевтична композиція у формі гранул, що містить езлікарбазепіну ацетат |
RU2639120C2 (ru) | 2011-08-26 | 2017-12-19 | Биал-Портела Энд Ка, С.А. | Лечение с использованием ацетата эсликарбазепина или эсликарбазепина |
EP3103444A1 (en) | 2015-06-09 | 2016-12-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical compositions of lacosamide and eslicarbazepine |
ES2903037T3 (es) | 2015-12-18 | 2022-03-30 | Jubilant Generics Ltd | Formas de dosificación orales sólidas de eslicarbazepina |
WO2018004391A1 (ru) * | 2016-06-29 | 2018-01-04 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина |
CN106913550B (zh) * | 2017-03-10 | 2019-12-17 | 扬子江药业集团北京海燕药业有限公司 | 一种醋酸艾司利卡西平片的制备方法 |
US11318145B2 (en) | 2018-09-25 | 2022-05-03 | Jubilant Generics Limited | Eslicarbazepine suspension |
WO2019058354A1 (en) * | 2017-09-25 | 2019-03-28 | Jubilant Generics Limited | SUSPENSION OF ESLICARBAZÉPINE |
EA037195B1 (ru) * | 2018-03-28 | 2021-02-18 | Акционерное Общество "Химфарм" | Биологически активная добавка для улучшения функционального состояния дыхательной системы и восстановления иммунной системы (варианты) |
US20220127567A1 (en) | 2018-09-14 | 2022-04-28 | Keio University | Method for producing astrocytes |
HUP1900153A1 (hu) | 2019-05-14 | 2020-11-30 | Meditop Gyogyszeripari Kft | Eszlikarbazepin-acetát tartalmú granulátum, ennek elõállítása, ezt tartalmazó egyéb gyógyszerkészítmények, és ezek alkalmazása |
US20210346324A1 (en) * | 2020-05-05 | 2021-11-11 | NeuroBo Therapeutics, Inc. | Niclosamide Formulations and Methods of Use |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
US6296873B1 (en) * | 1997-01-23 | 2001-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release delivery system for carbamazephine derivatives |
CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
GB9721497D0 (en) | 1997-10-09 | 1997-12-10 | Ciba Geigy Ag | Organic compounds |
BR9813808A (pt) * | 1997-12-19 | 2002-05-28 | Smithkline Beecham Corp | Processo para produção de comprimidos para dispersão na mordida |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
IN190699B (hu) * | 2001-02-02 | 2003-08-16 | Sun Pharmaceutical Ind Ltd | |
GB0111566D0 (en) | 2001-05-11 | 2001-07-04 | Portela & Ca Sa | Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide |
GB0112812D0 (en) | 2001-05-25 | 2001-07-18 | Portela & Ca Sa | Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom |
WO2003075830A2 (en) * | 2002-03-14 | 2003-09-18 | Sun Pharmaceutical Industries Limited | Oral controlled drug delivery system containing carbamazepine |
DE10224170A1 (de) | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
MXPA04011801A (es) | 2002-05-31 | 2005-09-12 | Desitin Arzneimittel Gmbh | Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa. |
DE10230027A1 (de) | 2002-07-04 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen auf der Basis von Natriumkanalblockern und Magnesiumsalzen |
GB0221956D0 (en) | 2002-09-20 | 2002-10-30 | Novartis Ag | Organic compounds |
EP1553934A1 (en) | 2002-10-17 | 2005-07-20 | Novartis AG | Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
US20040087642A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
GB2401605A (en) | 2003-05-12 | 2004-11-17 | Portela & Ca Sa | Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof |
EP1750717B1 (en) * | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
CN1934145B (zh) | 2004-03-17 | 2011-01-19 | 帝斯曼知识产权资产管理有限公司 | 包括脒配体的聚合催化剂 |
PE20051156A1 (es) | 2004-03-22 | 2006-02-13 | Novartis Ag | Formulaciones de matriz orales que comprenden licarbazepina |
AR048672A1 (es) | 2004-03-22 | 2006-05-17 | Novartis Ag | Tabletas de desintegracion que comprenden licarbazepina |
GB2416167A (en) | 2004-07-13 | 2006-01-18 | Portela & Ca Sa | Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides |
EP1787642A1 (en) | 2004-11-10 | 2007-05-23 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
GB0425320D0 (en) | 2004-11-17 | 2004-12-22 | Johnson Matthey Plc | Diamines |
GB2422149A (en) | 2005-01-14 | 2006-07-19 | Portela & Ca Sa | Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide |
PT2380575E (pt) | 2005-05-06 | 2015-06-17 | Bial Portela & Ca Sa | Acetato de eslicarbazepina e utilização |
MX366496B (es) | 2005-05-06 | 2019-07-11 | Bial Portela & Ca Sa | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. |
US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
US8059672B2 (en) | 2005-05-18 | 2011-11-15 | Sprint Communications Company L.P. | Internet communications between wireless base stations and service nodes |
US20070071819A1 (en) * | 2005-05-30 | 2007-03-29 | Kesarwani Amit K | Multiple unit modified release compositions of carbamazepine and process for their preparation |
US20090143360A1 (en) | 2005-07-08 | 2009-06-04 | Muhammed Safadi | Oxcarbazepine Formulation |
GB0515690D0 (en) | 2005-07-29 | 2005-09-07 | Portela & Ca Sa | Asymmetric catalytic reduction |
WO2007029093A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Pharmaceutical dosage forms of oxcarbazepine |
CA2630240A1 (en) | 2006-01-31 | 2007-08-09 | Teva Pharmaceutical Industries Ltd. | Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution |
CA2634879A1 (en) | 2006-01-31 | 2007-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical formulations of oxcarbazepine and methods for its preparation |
GB0603008D0 (en) | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
GB2437078A (en) | 2006-04-11 | 2007-10-17 | Portela & Ca Sa | 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives |
WO2008037044A1 (en) | 2006-09-27 | 2008-04-03 | Medley S.A. Indústria Farmacêutica | Oxcarbazepine-containing oral formulation and a process to obtain the same |
US20080138403A1 (en) | 2006-12-08 | 2008-06-12 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms of oxcarbazepine |
US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
ES2903037T3 (es) | 2015-12-18 | 2022-03-30 | Jubilant Generics Ltd | Formas de dosificación orales sólidas de eslicarbazepina |
-
2008
- 2008-10-23 US US12/257,240 patent/US8372431B2/en active Active
- 2008-10-24 JP JP2010530951A patent/JP2011500797A/ja active Pending
- 2008-10-24 PT PT161806872T patent/PT3202392T/pt unknown
- 2008-10-24 ES ES16180687T patent/ES2898202T3/es active Active
- 2008-10-24 HU HUE08842368A patent/HUE030788T2/hu unknown
- 2008-10-24 RU RU2010121135/15A patent/RU2546521C2/ru active
- 2008-10-24 KR KR1020167036806A patent/KR20170004034A/ko active Search and Examination
- 2008-10-24 KR KR1020107011233A patent/KR20100093057A/ko active Application Filing
- 2008-10-24 AR ARP080104652A patent/AR069031A1/es unknown
- 2008-10-24 PT PT88423686T patent/PT2214636T/pt unknown
- 2008-10-24 RS RS20160895A patent/RS55376B1/sr unknown
- 2008-10-24 PL PL08842368T patent/PL2214636T3/pl unknown
- 2008-10-24 CN CN200880112983A patent/CN101848698A/zh active Pending
- 2008-10-24 EP EP16180687.2A patent/EP3202392B1/en active Active
- 2008-10-24 KR KR1020187037643A patent/KR102116087B1/ko active IP Right Grant
- 2008-10-24 AU AU2008317584A patent/AU2008317584B2/en active Active
- 2008-10-24 CA CA2703313A patent/CA2703313C/en active Active
- 2008-10-24 WO PCT/PT2008/000043 patent/WO2009054743A1/en active Application Filing
- 2008-10-24 UA UAA201006417A patent/UA110012C2/ru unknown
- 2008-10-24 LT LTEP08842368.6T patent/LT2214636T/lt unknown
- 2008-10-24 ES ES08842368.6T patent/ES2607002T3/es active Active
- 2008-10-24 DK DK08842368.6T patent/DK2214636T3/en active
- 2008-10-24 BR BRPI0818680-4A patent/BRPI0818680B1/pt active IP Right Grant
- 2008-10-24 MX MX2010004323A patent/MX2010004323A/es active IP Right Grant
- 2008-10-24 SI SI200831687A patent/SI2214636T1/sl unknown
- 2008-10-24 EP EP08842368.6A patent/EP2214636B1/en active Active
-
2010
- 2010-04-18 IL IL205160A patent/IL205160A0/en unknown
-
2013
- 2013-01-30 US US13/754,439 patent/US20130150348A1/en not_active Abandoned
- 2013-12-17 US US14/108,615 patent/US9566244B2/en active Active
-
2014
- 2014-07-10 JP JP2014141894A patent/JP6043758B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-27 JP JP2016147183A patent/JP2017014233A/ja active Pending
- 2016-10-12 HR HRP20161329TT patent/HRP20161329T1/hr unknown
- 2016-12-14 CY CY20161101294T patent/CY1118350T1/el unknown
-
2017
- 2017-01-04 US US15/397,945 patent/US10912781B2/en active Active
-
2018
- 2018-06-26 JP JP2018120334A patent/JP2018172407A/ja active Pending
-
2021
- 2021-01-29 US US17/248,581 patent/US20210322436A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10912781B2 (en) | Pharmaceutical composition comprising licarbazepine acetate | |
US4950484A (en) | Pharmaceutical tablet, pharmaceutical granulate and process for their preparation | |
US4343789A (en) | Sustained release pharmaceutical composition of solid medical material | |
US20110014282A1 (en) | Pharmaceutical composition for poorly soluble drugs | |
KR20090092288A (ko) | 뉴로키닌 길항제를 포함하는 제약 제형 | |
JP2001503734A (ja) | カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物 | |
JP6328138B2 (ja) | N−[5−[2−(3,5−ジメトキシフェニル)エチル]−2h−ピラゾール−3−イル]−4−[(3r,5s)−3,5−ジメチルピペラジン−1−イル]ベンズアミドの医薬製剤 | |
AU2003217703A1 (en) | Diphenhydramine tannate solid dose compositions and methods of use | |
HU205850B (en) | Systhem of erosion-regulated release of the active components and process for producing it | |
KR20000022424A (ko) | 높은 양의 약을 함유하는, 신속-붕해되고 신속-용해되는 조성물제조용 과립 | |
HUE029193T2 (hu) | Tiokolhikozid késleltetett hatóanyag leadású gyógyszerkészítményei |